Societal CDMO, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US75629F1093
USD
1.10
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2023)

FII

1.37%

Held by 4 FIIs

DII

90.75%

Held by 15 DIIs

Promoter

0.00%

How big is Societal CDMO, Inc.?

22-Jun-2025

As of Apr 09, Societal CDMO, Inc. has a market capitalization of 116.26 million and reported net sales of 94.64 million with a net profit of -13.27 million over the last four quarters. The company has shareholder's funds of 58.66 million and total assets of 153.47 million as of Dec 23.

Market Cap: As of Apr 09, Societal CDMO, Inc. has a market capitalization of 116.26 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Societal CDMO, Inc. reported net sales of 94.64 million and a net profit of -13.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company has shareholder's funds amounting to 58.66 million and total assets of 153.47 million.

Read More

What does Societal CDMO, Inc. do?

22-Jun-2025

Societal CDMO, Inc. is a clinical-stage specialty pharmaceutical company focused on developing non-opioid treatments for serious acute pain. As of December 2023, it reported net sales of $28 million and a market cap of $116.26 million.

Overview:<BR>Societal CDMO, Inc. is a clinical-stage specialty pharmaceutical company engaged in developing non-opioid products for the treatment of serious acute pain, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 28 Million (Quarterly Results - Dec 2023) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2023) <BR>Market cap: USD 116.26 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 5,338.60% <BR>Debt Equity: 0.51 <BR>Return on Equity: -18.45% <BR>Price to Book: 1.98<BR><BR>Contact Details:<BR>Address: 490 Lapp Rd, MALVERN PA: 19355-1212 <BR>Tel: ['1 484 3952400', '1 212 6001902'] <BR>Fax: 1 484 3952471 <BR>Website: https://recropharma.com/

Read More

Who are in the management team of Societal CDMO, Inc.?

22-Jun-2025

As of March 2022, the management team of Societal CDMO, Inc. includes Independent Chairman Wayne Weisman, President and CEO J. David Enloe, and Independent Directors William Ashton, Michael Berelowitz, Winston Churchill, and Bryan Reasons. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Societal CDMO, Inc. includes the following individuals:<BR><BR>- Mr. Wayne Weisman, who serves as the Independent Chairman of the Board.<BR>- Mr. J. David Enloe, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. William Ashton, an Independent Director.<BR>- Dr. Michael Berelowitz, an Independent Director.<BR>- Mr. Winston Churchill, an Independent Director.<BR>- Mr. Bryan Reasons, an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 116 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5,338.60%

stock-summary
Debt Equity

0.51

stock-summary
Return on Equity

-18.45%

stock-summary
Price to Book

1.98

Revenue and Profits:
Net Sales:
28 Million
(Quarterly Results - Dec 2023)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
181.33%
0%
181.33%
6 Months
150.57%
0%
150.57%
1 Year
2.8%
0%
2.8%
2 Years
-34.91%
0%
-34.91%
3 Years
-66.26%
0%
-66.26%
4 Years
-87.57%
0%
-87.57%
5 Years
-85.14%
0%
-85.14%

Societal CDMO, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.78%
EBIT Growth (5y)
14.56%
EBIT to Interest (avg)
-0.14
Debt to EBITDA (avg)
14.89
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.75
Tax Ratio
1.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
69.25%
ROCE (avg)
0.14%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.98
EV to EBIT
-130.45
EV to EBITDA
18.80
EV to Capital Employed
1.65
EV to Sales
1.55
PEG Ratio
NA
Dividend Yield
5338.60%
ROCE (Latest)
-1.26%
ROE (Latest)
-18.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 10 Schemes (7.87%)

Foreign Institutions

Held by 4 Foreign Institutions (1.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 17.37% vs 8.26% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 82.61% vs -43.75% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.70",
          "val2": "23.60",
          "chgp": "17.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.90",
          "val2": "0.50",
          "chgp": "1,080.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "2.90",
          "chgp": "-10.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-4.60",
          "chgp": "82.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "128.60%",
          "val2": "-74.50%",
          "chgp": "20.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 4.88% vs 19.63% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 33.17% vs -74.56% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.60",
          "val2": "90.20",
          "chgp": "4.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.10",
          "val2": "8.60",
          "chgp": "-17.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.00",
          "val2": "14.10",
          "chgp": "-29.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "-5.00",
          "chgp": "64.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.30",
          "val2": "-19.90",
          "chgp": "33.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.60%",
          "val2": "3.10%",
          "chgp": "-2.17%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQstock-summary
Dec'23
Sep'23
Change(%)
Net Sales
27.70
23.60
17.37%
Operating Profit (PBDIT) excl Other Income
5.90
0.50
1,080.00%
Interest
2.60
2.90
-10.34%
Exceptional Items
-1.80
0.00
Consolidate Net Profit
-0.80
-4.60
82.61%
Operating Profit Margin (Excl OI)
128.60%
-74.50%
20.31%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2023 is 17.37% vs 8.26% in Sep 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is 82.61% vs -43.75% in Sep 2023

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
94.60
90.20
4.88%
Operating Profit (PBDIT) excl Other Income
7.10
8.60
-17.44%
Interest
10.00
14.10
-29.08%
Exceptional Items
-1.80
-5.00
64.00%
Consolidate Net Profit
-13.30
-19.90
33.17%
Operating Profit Margin (Excl OI)
-18.60%
3.10%
-2.17%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 4.88% vs 19.63% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 33.17% vs -74.56% in Dec 2022

stock-summaryCompany CV
About Societal CDMO, Inc. stock-summary
stock-summary
Societal CDMO, Inc.
Pharmaceuticals: Major
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
Company Coordinates stock-summary
Company Details
490 Lapp Rd , MALVERN PA : 19355-1212
stock-summary
Tel: 1 484 39524001 212 6001902
stock-summary
Registrar Details